Actelion Pharmaceuticals announced that the FDA has approved the brand name Veletri for its epoprostenol for injection. Veletri has been available since April 2010 for the long-term intravenous treatment of primary pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Veletri-labeled product will be available by early fourth quarter of 2010.

For more information call (866) 344-4874 or visit www1.actelion.us.